Propentofylline, a CNS glial modulator does not decrease pain in post-herpetic neuralgia patients: In vitro evidence for differential responses in human and rodent microglia and macrophages

Experimental Neurology

Volumn 234, Issue 2, 2012, Pages 340-350

  Landry, Russell P ^a,b   Jacobs, Valerie L ^a,b   Romero Sandoval, Edgar Alfonso ^a,b,c   DeLeo, Joyce A ^a,b,c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Neuroscience Center at Dartmouth   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Chronic pain; Interleukin 1 ; Nitric oxide; Proinflammatory cytokines; THP 1 cells; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 1BETA; NITRATE; PROPENTOFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

CELL TYPE; CONCENTRATION RESPONSE; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; IC 50; MICROGLIA; NONHUMAN; PERITONEUM MACROPHAGE; PHARMACOLOGICAL BLOCKING; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; REVIEW;

ANIMALS; HUMANS; MACROPHAGES; MICROGLIA; NEURALGIA, POSTHERPETIC; TUMOR NECROSIS FACTOR-ALPHA; XANTHINES;

EID: 84858157952     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.11.006     Document Type: Review

References (59)

1. Abi-Rached, L., Moesta, A.K., Rajalingam, R., Guethlein, L.A., Parham P., 2010. Human-specific evolution and adaptation led to major qualitative differences in the variable receptors of human and chimpanzee natural killer cells. PLoS Genet. 6, e1001192.
2. Arruda J.L., et al. Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain. Brain Res. 2000, 879:216-225.
3. Austin P.J., Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J. Neuroimmunol. 2010, 229:26-50.
4. Bacchetti P., et al. Breaking free of sample size dogma to perform innovative translational research. Sci. Transl. Med. 2011, 3(87):ps24.
5. Berlin J.A. N-of-1 clinical trials should be incorporated into clinical practice. J Clin Epidemiol 2010, 63:1283-1284.
6. Caggiano A.O., et al. Long-term elevation of cyclooxygenase-2, but not lipoxygenase, in regions synaptically distant from spreading depression. J. Comp. Neurol. 1996, 376:447-462.
7. Cao L., DeLeo J.A. CNS-infiltrating CD4+ T lymphocytes contribute to murine spinal nerve transection-induced neuropathic pain. Eur. J. Immunol. 2008, 38:448-458.
8. Cao L., et al. The contributing role of CD14 in toll-like receptor 4 dependent neuropathic pain. Neuroscience 2009, 158:896-903.
9. Casula M., et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 2011, 179:233-243.
10. Cigana C., et al. Pseudomonas aeruginosa exploits lipid A and muropeptides modification as a strategy to lower innate immunity during cystic fibrosis lung infection. PLoS One 2009, 4:e8439.
11. Costigan M., et al. T-cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity. J. Neurosci. 2009, 29:14415-14422.
12. Cuellar J.M., et al. Cytokine evaluation in individuals with low back pain using discographic lavage. Spine J. 2010, 10:212-218.
13. Dalziel R.G., et al. Allodynia in rats infected with varicella zoster virus-a small animal model for post-herpetic neuralgia. Brain Res Brain Res Rev 2004, 46:234-242.
14. De Alba J., et al. GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain. Pain 2006, 120:170-181.
15. DeLeo J.A., Yezierski R.P. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 2001, 90:1-6.
16. Durafourt B.A., et al. Differential responses of human microglia and blood-derived myeloid cells to FTY720. J. Neuroimmunol. 2011, 230:10-16.
17. El-Mahmoudy A., et al. Thymoquinone suppresses expression of inducible nitric oxide synthase in rat macrophages. Int. Immunopharmacol. 2002, 2:1603-1611.
18. Fields R.D. New culprits in chronic pain. Sci. Am. 2009, 301:50-57.
19. Freidlin B., Simon R. Evaluation of randomized discontinuation design. J. Clin. Oncol. 2005, 23:5094-5098.
20. Garry E.M., et al. Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs. Pain 2005, 118:97-111.
21. Garry E.M., et al. Activation of p38 and p42/44 MAP kinase in neuropathic pain: involvement of VPAC2 and NK2 receptors and mediation by spinal glia. Mol. Cell. Neurosci. 2005, 30:523-537.
22. Ginhoux F., et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841-845.
23. Guha M., Mackman N. LPS induction of gene expression in human monocytes. Cell. Signal. 2001, 13:85-94.
24. Hashioka S., et al. Differential expression of interferon-gamma receptor on human glial cells in vivo and in vitro. J. Neuroimmunol. 2010, 225:91-99.
25. Hasnie F.S., et al. Further characterization of a rat model of varicella zoster virus-associated pain: relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience 2007, 144:1495-1508.
26. Hauser C.J., et al. Production of interleukin-10 in human fracture soft-tissue hematomas. Shock 1996, 6:3-6.
27. Hewitt D.J., et al. Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain 2011, 152:514-521.
28. Hickey W.F., Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988, 239:290-292.
29. Homma, Y., Brull, S.J., Zhang, J.M., 2002. A comparison of chronic pain behavior following local application of tumor necrosis factor alpha to the normal and mechanically compressed lumbar ganglia in the rat. Pain 95, 239-246.
30. Jack C.S., et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J. Immunol. 2005, 175:4320-4330.
31. Kiguchi N., et al. Macrophage inflammatory protein-1alpha mediates the development of neuropathic pain following peripheral nerve injury through interleukin-1beta up-regulation. Pain 2010, 149:305-315.
32. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19:312-318.
33. Lam H.H., et al. Induction of spinal cord neuronal nitric oxide synthase (NOS) after formalin injection in the rat hind paw. Neurosci. Lett. 1996, 210:201-204.
34. Lambert C., et al. Distinct migratory and cytokine responses of human microglia and macrophages to ATP. Brain Behav Immun 2010, 24:1241-1248.
35. Liu Z., et al. Differential regulation of human and murine P-selectin expression and function in vivo. J Exp Med 2010, 207:2975-2987.
36. McMahon S.B., Malcangio M. Current challenges in glia-pain biology. Neuron 2009, 64:46-54.
37. Merrill J.E., Benveniste E.N. Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci. 1996, 19:331-338.
38. Mishima T., Hirase H. In vivo intracellular recording suggests that gray matter astrocytes in mature cerebral cortex and hippocampus are electrophysiologically homogeneous. J. Neurosci. 2010, 30:3093-3100.
39. Murphy A.J., et al. Estradiol suppresses NF-kappa B activation through coordinated regulation of let-7a and miR-125b in primary human macrophages. J. Immunol. 2010, 184:5029-5037.
40. Murata, Y., Onda, A., Rydevik, B., Takahashi, I., Takahashi, K., Olmarker, K., 2006. Changes in pain behavior and histologic changes caused by application of tumor necrosis factor-alpha to the dorsal root ganglion in rats. Spine 31, 530-535.
41. Nutile-McMenemy N., et al. Minocycline decreases in vitro microglial motility, beta1-integrin, and Kv1.3 channel expression. J. Neurochem. 2007, 103:2035-2046.
42. Obata K., et al. Toll-like receptor 3 contributes to spinal glial activation and tactile allodynia after nerve injury. J. Neurochem. 2008, 105:2249-2259.
43. Oksenberg D., et al. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature 1992, 360:161-163.
44. Parker E.M., et al. A single amino acid difference accounts for the pharmacological distinctions between the rat and human 5-hydroxytryptamine1B receptors. J. Neurochem. 1993, 60:380-383.
45. Peri F., et al. Exploring the LPS/TLR4 signal pathway with small molecules. Biochem. Soc. Trans. 2010, 38:1390-1395.
46. Ponomarev E.D., et al. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med 2011, 17:64-70.
47. Romero-Sandoval A., et al. A comparison of spinal Iba1 and GFAP expression in rodent models of acute and chronic pain. Brain Res 2008, 1219:116-126.
48. Sorkin L.S., et al. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 1997, 81:255-262.
49. Sweitzer S., et al. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 2001, 103:529-539.
50. Sweitzer S.M., et al. Focal peripheral nerve injury induces leukocyte trafficking into the central nervous system: potential relationship to neuropathic pain. Pain 2002, 100:163-170.
51. Sweitzer S.M., et al. Propentofylline attenuates vincristine-induced peripheral neuropathy in the rat. Neurosci. Lett. 2006, 400:258-261.
52. Sweitzer S.M., et al. Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. J. Pharmacol. Exp. Ther. 2001, 297:1210-1217.
53. Tanga F.Y., et al. The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5856-5861.
54. Tawfik V.L., et al. Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury. Brain Behav Immun 2007, 21:238-246.
55. Tawfik V.L., et al. Propentofylline-induced astrocyte modulation leads to alterations in glial glutamate promoter activation following spinal nerve transection. Neuroscience 2008, 152:1086-1092.
56. Temple R.J. Enrichment designs: efficiency in development of cancer treatments. J. Clin. Oncol. 2005, 23:4838-4839.
57. Tsuda M., et al. IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8032-8037.
58. Watkins L.R., Maier S.F. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003, 2:973-985.
59. Whiteside G.T., et al. Predictive validity of animal pain models? A comparison of the pharmacokinetic-pharmacodynamic relationship for pain drugs in rats and humans. Neuropharmacology 2008, 54:767-775.